Search

Your search keyword '"Greggi S"' showing total 3 results
Start Over Author "Greggi S" Journal british journal of cancer
3 results on '"Greggi S"'

1. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis

Author

Maggioni, A., BENEDETTI PANICI, Pierluigi, Panici, P. B., Dell'Anna, T., Landoni, F., Lissoni, A., Pellegrino, A., Rossi, R. S., Chiari, S., Campagnutta, E., Greggi, S., Angioli, R., Manci, N., Calcagno, Marco, Scambia, G., Fossati, R., Floriani, I., Torri, V., Grassi, R., Mangioni, C., Maggioni, A, Benedetti Panici, P, Dell'Anna, T, Landoni, F, Lissoni, A, Pellegrino, A, Rossi, R, Chiari, S, Campagnutta, E, Greggi, S, Angioli, R, Manci, N, Calcagno, M, Scambia, G, Fossati, R, Floriani, I, Torri, V, Grassi, R, and Mangioni, C

Subjects
Adult, Pelvic Neoplasm, Cancer Research, medicine.medical_specialty, Randomization, medicine.medical_treatment, Urology, ovarian carcinoma, randomised clinical trial, lymphadenectomy, surgery, Risk Factors, Ovarian carcinoma, Antineoplastic Combined Chemotherapy Protocols, Clinical Studies, medicine, Humans, Stage (cooking), Survival rate, Pelvic Neoplasms, Neoplasm Staging, Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocol, business.industry, Risk Factor, Ovarian Neoplasm, Hazard ratio, Lymph Node, Lymphatic Metastasi, Middle Aged, medicine.disease, Surgery, Survival Rate, Treatment Outcome, Oncology, Chemotherapy, Adjuvant, Lymphatic Metastasis, Disease Progression, Lymph Node Excision, Female, Lymphadenectomy, Lymph Nodes, Lymph, Ovarian cancer, business, Human
Abstract

No randomised trials have addressed the value of systematic aortic and pelvic lymphadenectomy (SL) in ovarian cancer macroscopically confined to the pelvis. This study was conducted to investigate the role of SL compared with lymph nodes sampling (CONTROL) in the management of early stage ovarian cancer. A total of 268 eligible patients with macroscopically intrapelvic ovarian carcinoma were randomised to SL (N=138) or CONTROL (N=130). The primary objective was to compare the proportion of patients with retroperitoneal nodal involvement between the two groups. Median operating time was longer and more patients required blood transfusions in the SL arm than the CONTROL arm (240 vs 150 min, P

Published
2006

2. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group

Author

Pignata, S, primary, Scambia, G, additional, Pisano, C, additional, Breda, E, additional, Di Maio, M, additional, Greggi, S, additional, Ferrandina, G, additional, Lorusso, D, additional, Zagonel, V, additional, Febbraro, A, additional, Riva, N, additional, De Rosa, V, additional, Gallo, C, additional, and Perrone, F, additional

Published
2007
Full Text
View/download PDF

3. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).

Author

Musacchio L, Califano D, Bartoletti M, Arenare L, Lorusso D, Losito NS, Cormio G, Greggi S, Raspagliesi F, Valabrega G, Salutari V, Pisano C, Spina A, Russo D, Del Sesto M, Canzonieri V, Ferraù F, Zannoni GF, Loizzi V, Ghizzoni V, Casanova C, Tuninetti V, Ducceschi M, Del Vecchio V, Scalone S, Priolo D, Perrone F, Scambia G, and Pignata S

Subjects
Female, Humans, Prospective Studies, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras), Retrospective Studies, Cystadenocarcinoma, Serous pathology, Ovarian Neoplasms drug therapy, Ovarian Neoplasms genetics, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms genetics
Abstract

Background: Low-grade serous ovarian and peritoneal cancer (LGSC) is a rare disease and few data on the clinical and genomic landscape have been published., Methods: A retrospective analysis of patients diagnosed with LGSC between 1996 and 2019 was conducted in MITO centers. Objective Response Rate (ORR) to treatments, progression-free survival (PFS) and overall survival (OS) were assessed. Additionally, the tumor molecular profile of 56 patients was evaluated using the Next Generation Sequencing (NGS) FoundationOne CDX (Foundation Medicine®)., Results: A total of 128 patients with complete clinical data and pathologically confirmed diagnosis of LGSC were identified. ORR to first and subsequent therapies were 23.7% and 33.7%, respectively. PFS was 43.9 months (95% CI:32.4-53.1) and OS was 105.4 months (95% CI: 82.7-not reached). The most common gene alterations were: KRAS (n = 12, 21%), CDKN2A/B (n = 11, 20%), NRAS (n = 8, 14%), FANCA (n = 8, 14%), NF1 (n = 7, 13%) and BRAF (n = 6, 11%). Unexpectedly, pathogenetic BRCA1 (n = 2, 4%), BRCA2 (n = 1, 2%) and PALB2 (n = 1, 2%) mutations were found., Conclusions: MITO 22 suggests that LGSC is an heterogenous disease for both its clinical behavior in response to standard therapies and its molecular alterations. Future prospective studies should test treatments according to biological and molecular tumor's characteristics., Clinical Trial Registration: This study is registered under NCT02408536 on ClinicalTrials.gov ., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results